Research progress on the role of fibroblast activation protein in diagnosis and treatment of cancer

被引:8
作者
Wu, Zhaoye [1 ,2 ]
Hua, Yuqi [1 ,2 ]
Shen, Qiaoling [1 ,2 ]
Yu, Chunjing [1 ]
机构
[1] Jiangnan Univ, Wuxi Sch Med, Wuxi, Jiangsu, Peoples R China
[2] Jiangnan Univ, Affiliated Hosp, Dept Nucl Med, 1000,Hefeng Rd,Xuelang St, Wuxi 214122, Jiangsu, Peoples R China
关键词
cancer-associated fibroblasts; fibroblast activation protein; fibroblast activation protein inhibitor; PET; DIPEPTIDYL-PEPTIDASE-IV; PHASE-II TRIAL; TUMOR MICROENVIRONMENT; STROMAL FIBROBLASTS; MOLECULAR-CLONING; ALPHA; EXPRESSION; FAP; IMMUNOTHERAPY; SPECIFICITY;
D O I
10.1097/MNM.0000000000001565
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Fibroblast activation protein (FAP) is a type II transmembrane protein, which is over-expressed in cancer-associated fibroblasts (CAFs). CAFs are tumor stromal cells that constitute a major component of cancer volume and are reportedly related to tumorigenesis, angiogenesis, metastasis, promotion of drug resistance and induction of tumor immunity. FAP is widely acknowledged as the signature protein of CAFs. At present, FAP inhibitors (FAPI) have achieved ideal results in tumor PET/computed tomography (CT) imaging. Theoretically, FAP-targeted drugs can inhibit tumor progression. Nonetheless, no satisfactory therapeutic effect has been observed so far, which has impeded their implementation in clinical practice. In this review, we describe the characteristics of FAP and its role in the occurrence and development of cancer. We also highlight the potential value of targeting FAP to improve current diagnostic and therapeutic approaches.
引用
收藏
页码:746 / 755
页数:10
相关论文
共 85 条
  • [1] Adams Sharlene, 2005, Proceedings of the American Association for Cancer Research Annual Meeting, V46, P153
  • [2] Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein α
    Aertgeerts, K
    Levin, I
    Shi, LH
    Snell, GP
    Jennings, A
    Prasad, GS
    Zhang, YM
    Kraus, ML
    Salakian, S
    Sridhar, V
    Wijnands, R
    Tennant, MG
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (20) : 19441 - 19444
  • [3] Unveiling the Role of Nuclear Transport in Epithelial-to-Mesenchymal Transition
    Azmi, Asfar S.
    [J]. CURRENT CANCER DRUG TARGETS, 2013, 13 (09) : 906 - 914
  • [4] Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results
    Baum, Richard P.
    Schuchardt, Christiane
    Singh, Aviral
    Chantadisai, Maythinee
    Robiller, Franz C.
    Zhang, Jingjing
    Mueller, Dirk
    Eismant, Alexander
    Almaguel, Frankis
    Zboralski, Dirk
    Osterkamp, Frank
    Hoehne, Aileen
    Reineke, Ulrich
    Smerling, Christiane
    Kulkarni, Harshad R.
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (03) : 415 - 423
  • [5] The Role of Tumor Stroma in Cancer Progression and Prognosis Emphasis on Carcinoma-Associated Fibroblasts and Non-small Cell Lung Cancer
    Bremnes, Roy M.
    Donnem, Tom
    Al-Saad, Samer
    Al-Shibli, Khalid
    Andersen, Sigve
    Sirera, Rafael
    Camps, Carlos
    Marinez, Inigo
    Busund, Lill-Tove
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (01) : 209 - 217
  • [6] RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis
    Brunker, Peter
    Wartha, Katharina
    Friess, Thomas
    Grau-Richards, Sandra
    Waldhauer, Inja
    Koller, Claudia Ferrara
    Weiser, Barbara
    Majety, Meher
    Runza, Valeria
    Niu, Huifeng
    Packman, Kathryn
    Feng, Ningping
    Daouti, Sherif
    Hosse, Ralf J.
    Mossner, Ekkehard
    Weber, Thomas G.
    Herting, Frank
    Scheuer, Werner
    Sade, Hadassah
    Shao, Cuiying
    Liu, Bin
    Wang, Peng
    Xu, Gary
    Vega-Harring, Suzana
    Klein, Christian
    Bosslet, Klaus
    Umana, Pablo
    [J]. MOLECULAR CANCER THERAPEUTICS, 2016, 15 (05) : 946 - 957
  • [7] Targeting fibroblast activation protein in cancer - Prospects and caveats
    Busek, Petr
    Mateu, Rosana
    Zubal, Michal
    Kotackova, Lenka
    Sedo, Aleksi
    [J]. FRONTIERS IN BIOSCIENCE-LANDMARK, 2018, 23 : 1933 - 1968
  • [8] Increased tissue and circulating levels of dipeptidyl peptidase-IV enzymatic activity in patients with pancreatic ductal adenocarcinoma
    Busek, Petr
    Vanickova, Zdislava
    Hrabal, Petr
    Brabec, Marek
    Fric, Premysl
    Zavoral, Miroslav
    Skrha, Jan
    Kmochova, Klara
    Laclav, Martin
    Bunganic, Bohus
    Augustyns, Koen
    Van der Veken, Pieter
    Sedo, Aleksi
    [J]. PANCREATOLOGY, 2016, 16 (05) : 829 - 838
  • [9] Will FAPI PET/CT Replace FDG PET/CT in the Next Decade? Point-An Important Diagnostic, Phenotypic, and Biomarker Role
    Calais, Jeremie
    Mona, Christine E.
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 2021, 216 (02) : 305 - 306
  • [10] Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [18F]FDG PET/CT findings
    Chen, Haojun
    Zhao, Liang
    Ruan, Dan
    Pang, Yizhen
    Hao, Bing
    Dai, Yaqing
    Wu, Xiurong
    Guo, Wei
    Fan, Chunlei
    Wu, Jingxun
    Huang, Weipeng
    Lin, Qin
    Sun, Long
    Wu, Hua
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (01) : 73 - 86